Analyst Marc Goodman of Leerink Partners maintained a Buy rating on Marinus (MRNS – Research Report), with a price target of $20.00.
Marc Goodman has given his Buy rating due to a combination of factors, including strong sales performance and promising pipeline prospects for Marinus Pharmaceuticals. The company reported fourth-quarter sales that met their pre-announced figures and provided a confident revenue guidance for the upcoming year. Moreover, with Marinus actively increasing the number of patients using Ztalmy and progressing with plans to expand into overseas markets, the company’s growth trajectory seems robust. Additionally, the successful enrollment for the RAISE trial of intravenous ganaxolone and the expected interim analysis in the second quarter signal potential catalysts for the stock’s performance.
Furthermore, Goodman’s optimism is supported by Marinus’s readiness for regulatory submissions, pending positive trial results. The anticipation of priority reviews for upcoming New Drug Application (NDA) submissions could significantly expedite Marinus’s go-to-market strategy for its treatments. The company’s strong cash position at the end of the year is also a key factor, with enough resources to sustain operations well into the following year. These aspects collectively underpin Goodman’s belief in the company’s potential and justify the Buy rating assigned to Marinus’s stock.
Goodman covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Jazz Pharmaceuticals, and Intra-Cellular Therapies. According to TipRanks, Goodman has an average return of 6.7% and a 44.85% success rate on recommended stocks.
In another report released yesterday, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $13.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Marinus (MRNS) Company Description:
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
Read More on MRNS:
